Aldafermin is under clinical development by NGM Biopharmaceuticals and currently in Phase II for Diarrhea. According to GlobalData, Phase II drugs for Diarrhea have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Aldafermin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aldafermin overview
Aldafermin (NGM-282) is under development for the treatment of type 2 diabetes, primary biliary cirrhosis, chronic diarrhea due to bile acid malabsorption (BAM), primary sclerosing cholangitis (PSC), functional constipation, non-alcoholic steatohepatitis (NASH), liver cirrhosis and liver fibrosis. The drug candidate is administered subcutaneously. NGM282 is an engineered recombinant protein variant of the ileal hormone human fibroblast growth factor 19 (FGF19). The drug candidate binds to FGFR4 and FGFR1.
NGM Biopharmaceuticals overview
NGM Biopharmaceuticals (NGM Bio) operates as a clinical-stage biopharmaceutical company that develops therapeutics for the treatment of cardio-metabolic, immuno-oncology, retinal and liver diseases and ophthalmic diseases. The company’s pipeline products include NGM707, NGM831, NGM438, NGM120, NGM621, MK-3655 and Aldafermin. Its NGM707 is a novel dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript and NGM831 is the potential to fight tumors by shifting myeloid cells from a suppressive state to a stimulatory state and promote anti-tumor activity. The company’s biologic platform incorporates multiple technologies to generate and screen monoclonal antibodies. NGM Bio is headquartered in San Francisco, California, the US.
For a complete picture of Aldafermin’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
